Erlotinib hydrochloride

CHF 60.00
In stock
SYN-1039-M0011 mgCHF 60.00
SYN-1039-M0055 mgCHF 84.00
SYN-1039-M01010 mgCHF 108.00
SYN-1039-M05050 mgCHF 144.00
SYN-1039-M100100 mgCHF 174.00
 
More Information
Product Details
Synonyms OSI774; CP-358774; Tarceva; NSC718781
Product Type Chemical
Properties
Formula C22H23N3O4 . HCl
MW 393.4 . 36.5
CAS 183319-69-9
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol.
Declaration Manufactured by SynKinase.
Other Product Data Target: EGFR | Kinase Group: RTK | Substrate: Tyrosine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key GTTBEUCJPZQMDZ-UHFFFAOYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Erlotinib inhibits EGFR tyrosine kinase auto-phosphorylation. Studies in cell lines and enzyme assays have shown that erlotinib inhibits EGFR at concentrations significantly lower than those needed to inhibit c-src and v-abl. It has an IC(50) of 2nM against EGFR. It is >1000-fold more sensitive for EGFR than for c-Src or v-Abl.
Product References
  1. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen: J.R. Johnson, et al.; Clin. Cancer Res. 11, 6414 (2005)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.